secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001104659-24-033990
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data
--------------------------------------------------------------------------------

- Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.
- Cash & equivalents $10.7M as of Dec 31, 2023; plus $6.5M March 5 offering and $8M ELOC (pending shareholder approval).
- Positive initial data from first 6 evaluable subjects: 5/6 had negligible/absent itch; all 6 showed skin score improvement.
- No safety concerns reported in either ongoing Netherton Syndrome study; enrollment age lowered to 14+.
- Expects cash runway to extend into H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/0001104659-24-033990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/tm248782d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer